KNOTUS Co.Ltd Market Cap ($290.80 Million)
Market Cap & Net Worth: KNOTUS Co.Ltd (278650)
KNOTUS Co.Ltd market cap. KNOTUS Co.Ltd (KQ:278650) has a market capitalization of $290.80 Million (₩429.11 Billion) as of November 5, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #14723 globally and #467 in its home market, demonstrating a -19.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying KNOTUS Co.Ltd's stock price ₩5080.00 by its total outstanding shares 84470472 (84.47 Million). Also see how efficiently does KNOTUS Co.Ltd generate cash for how efficiently the company converts equity into cash flow.
KNOTUS Co.Ltd Market Cap History (2019–2026)
KNOTUS Co.Ltd market cap history from 2019 to 2026. Data shows growth from $128.39 Million to $290.80 Million (3.56% CAGR). Check current stock price of KNOTUS Co.Ltd for real-time trading data and today's change.
Index Memberships
KNOTUS Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.14% | #143 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.14% | #143 of 1384 |
Weight: KNOTUS Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
KNOTUS Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how KNOTUS Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore KNOTUS Co.Ltd (278650) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
KNOTUS Co.Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $128.39 Million | $46.04 Billion | $4.20 Billion | 0.00x | 0.03x |
| 2020 | $157.81 Million | $58.52 Billion | $8.30 Billion | 0.00x | 0.02x |
| 2021 | $181.42 Million | $64.40 Billion | $11.03 Billion | 0.00x | 0.02x |
| 2022 | $266.19 Million | $86.28 Billion | -$3.00 Billion | 0.00x | N/A |
| 2023 | $176.89 Million | $52.81 Billion | -$164.04 Million | 0.00x | N/A |
| 2024 | $119.93 Million | $58.17 Billion | -$8.56 Billion | 0.00x | N/A |
Competitor Companies of 278650 by Market Capitalization
Companies near KNOTUS Co.Ltd in the global market cap rankings as of November 5, 2026. Also see KNOTUS Co.Ltd asset portfolio for a full breakdown of the balance sheet.
Key companies related to KNOTUS Co.Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of KNOTUS Co.Ltd (2019–2026)
Market capitalization of KNOTUS Co.Ltd from 2019 to today. Between 2019 and today, KNOTUS Co.Ltd's market cap moved from $128.39 Million to $ 290.80 Million, with a yearly change of 3.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩290.80 Million | +249.38% |
| 2025 | ₩83.23 Million | -30.60% |
| 2024 | ₩119.93 Million | -32.20% |
| 2023 | ₩176.89 Million | -33.55% |
| 2022 | ₩266.19 Million | +46.72% |
| 2021 | ₩181.42 Million | +14.96% |
| 2020 | ₩157.81 Million | +22.91% |
| 2019 | ₩128.39 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of KNOTUS Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $290.80 Million USD |
| MoneyControl | $290.80 Million USD |
| MarketWatch | $290.80 Million USD |
| marketcap.company | $290.80 Million USD |
| Reuters | $290.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more